学術集会・セミナー

Japanese English

General Information

Date : January 23 (Tuesday), 2018. 9:00-17:10
Venue : Toshi Center Hotel Tokyo, Cosmos Hall I
2-4-1 Hirakawa-cho, Chiyoda-ku, Tokyo 102-0093, Japan.
Tel: +81(0)3-3265-8211
(Map & Directions)
Theme : The profound impact of epigenetics on cancer molecular medicine
Organizing Committee:
    Chair
Minoru Yoshida (RIKEN)
    Organizing Committee Members
Hiroyuki Aburatani (University of Tokyo)
Akihiro Ito (Tokyo University of Pharmacy and Life Sciences)
Toshikazu Ushijima (National Cancer Center Research Institute)
Yutaka Kondo (Nagoya University)
Hiroyuki Seimiya (Japanese Foundation for Cancer Research)
Shiro Akinaga (AccuRna, Inc.)
Registration : Pre-registration required through Webpage or E-mail
Fee:   JPY1,000 for members of the Association
JPY3,000 for Non-members
(Paid in cash at the Workshop reception desk)
WS Secretariat : Center for Sustainable Resource Science, RIKEN
2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
E-mail:13trw-jamttc@riken.jp

Program

9:00 - 9:10
Opening Remarks

Hiroyuki Osada (President, The Japanese Association for Molecular Target Therapy of Cancer)

9:10 - 10:40
Workshop 1: Novel molecular targets for epigenomic therapy

Chair: Hiroyuki Seimiya
1. Dissecting cancer epigenome with iPS cell technology
Yasuhiro Yamada (The Institute of Medical Science, The University of Tokyo; Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University)
2. Chemical biology of BRD4 antagonists
Minoru Tanaka (Research Unit/Immunology & Inflammation, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation)
3. Precision cancer medicine based on gene aberrations: from kinases to chromatin regulators
Takashi Kohno (Division of Genome Biology, National Cancer Center Research Institute)

10:50 - 12:20
Workshop 2: New strategies based on epigenome

Chair: Toshikazu Ushijima
1. Targeted epigenetic modifications: novel therapeutic strategies using pyrrole-imidazole polyamide for disease therapy
Hiroki Nagase (Chiba Cancer Center Research Institute)
2. Molecular basis of endocrine therapy-resistant breast cancer and its therapeutic potential
Mitsuyoshi Nakao (Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University)
3. Targeting long non-coding RNA as a novel approach for cancer treatment
Yutaka Kondo (Division of Cancer Biology, Nagoya University Graduate School of Medicine)

12:30 - 13:30
Luncheon Seminar

Chair: Minoru Yoshida
Translation of pre-clinical hypotheses of tumor sensitivity to EZH2 inhibition, in NHL & solid tumors, via clinical development of tazemetostat
Stephen J. Blakemore (Epizyme, Inc.)

13:40 - 15:10
Workshop 3: Advances in epigenetic technologies and diagnosis

Chair: Hiroyuki Aburatani
1. ChILT - an Immunoprecipitation-free Epigenome Profiling Technology
Yasuyuki Ohkawa (Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University)
2. Epigenome editing and its potency
Izuho Hatada (Laboratory of Genome Science, Institute for Molecular and Cellular Regulation, Gunma University)
3. Precision medicine by epigenetic biomarkers
Toshikazu Ushijima (Division of Epigenomics, National Cancer Center Research Institute)

15:10 - 15:30 Coffee break

15:30 - 17:00
Workshop 4: Epigenomic drug discovery and translational researches

Chair: Shiro Akinaga
1. Challange to overcome targeted drug resistance in lung cancer by combined use of HDAC inhibitors
Seiji Yano (Division of Medical Oncology , Cancer Research Institute, Kanazawa University)
2. HDAC inhibitor in clinical development for breast cancer and translational approaches
Yozo Nishimura (Kyowa Hakko Kirin Co., Ltd.)
3. Development of cancer stem cell-targeted therapy based on inhibition of histone metyltransferase EZH1/2 and mutant IDH1
Issay Kitabayashi (Division of Hematological Malignancy, National Cancer Center Research Institute)

17:00 Closing Remarks

Minoru Yoshida (Organizing Committee Chair, The 13th Translational Research Workshop)

このページの先頭へ